A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

NCT03572231 · clinicaltrials.gov ↗

COMPLETED

Status

805

Enrollment

INDUSTRY

Sponsor class

Conditions

Overactive Bladder (OAB)

Interventions

DRUG: mirabegron
DEVICE: solifenacin
DRUG: darifenacin
DRUG: imidafenacin
DRUG: tolterodine
DRUG: oxybutynin
DRUG: trospium
DRUG: fesoterodine
DEVICE: propiverine

Sponsor

Astellas Pharma Singapore Pte. Ltd.